94 results about "Amine oxidase" patented technology

PCT No. PCT/EP96/03888 Sec. 371 Date Mar. 11, 1998 Sec. 102(e) Date Mar. 11, 1998 PCT Filed Sep. 4, 1996 PCT Pub. No. WO97/10054 PCT Pub. Date Mar. 20, 1997Olefins can be epoxidized using catalysts I where M is a metal of the 4th to 7th transition group of the Periodic Table of the Elements, L1 is an amine oxide, phosphine oxide, arsine oxide, pyridine N-oxide or pyridine ligand of the formula II, III, VII or VIII, L2 is a customary auxiliary ligand or a further ligand L1 or a free coordination site, X is oxo oxygen or an imido ligand, m is 1 or 2, and n is 1, 2 or 3.

LSD1, a homolog of nuclear amine oxidases, functions as a histone demethylase and transcriptional co-repressor. LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription. Lysine demethylation occurs via an oxidation reaction that generates formaldehyde. Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant de-repression of target genes, suggesting that LSD1 represses transcription via histone demethylation. The results thus identify a histone demethylase conserved from S. pombe to human and reveal dynamic regulation of histone methylation by both histone methylases and demethylases.

The invention relates to N-substituted acrylic amide synthesized through an amine oxide cracking elimination method and a method. The method is that the N-substituted acrylic amide is synthesized by beta-dialkyl amine-N-substituted acrylic amide (II) through the amine oxide cracking elimination method. The method includes the steps that (1), in water media, hydrogen peroxide performs oxidation on the beta-dialkyl amine-N-substituted acrylic amide (II), and then an amine oxide (III) solution is prepared; (2), a vacuum cracking elimination reaction is performed on the amide oxide in an aprotic solvent, so that N-mono-substituted acrylic amide or N, N-disubstituted acrylic amide is prepared. Beta-dialkyl amine-N-substituted acrylic amide (II) can be prepared with secondary amine R32NH as a protective agent and acrylic ester and alkylamine HNR1R2 as raw materials. According to the process route, the method has the advantages of being low in racking reaction temperature, high in yield and capable of preparing the mono-substituted acrylic amide and the disubstituted acrylic amide, and product monomers are not prone to self-polymerization.

The invention relates to a processing device of ammoniacal odor and spray liquid and operation method thereof, belonging to the filed of environmental protection. The processing device mainly comprises a biotrickling filtering tower (4), a washing tower (15), a hybrid regulating reservoir (24) and an anaerobic sequence batch reactor (29). The ammoniacal odor enters the biotrickling filtering tower (4) and the washing tower (15) after diffluence, gas purified through the two towers can reach emission requirement, the concentration of NOx in the recycled spray liquid inside the biotrickling filtering tower is gradually increased, and the concentration of NH4 in the recycled spray liquid inside the washing tower is gradually increased. The drainage frequency and amount of spray liquid in the two towers are controlled so that the spray liquid is merged into the hybrid regulating reservoir (24) and enters the anaerobic sequence batch reactor (29) after water quality is adjusted, and the effluent after anaerobic amine oxidase denitrogenate processing is used as spray water of biotrickling filtering tower and washing tower and thinned water of hybrid regulating reservoir. The invention has high odor clearance; on the premise that the system has good operation, spray water is cycled in the inner loop without secondary pollution, and the water source is saved.

The invention relates to an integrated detection reaction orifice plate and protein chip reagent box for detecting six indexes of diagnosis, forecast and prognosis of hepatitis, hepatocirrhosis and liver cancer, including hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), alpha-fetoprotein (AFP), alpha-L-Fucosidase (AFU), mono amine oxidase (MAO), hyaluronic acid (HA). And the orifice plate comprises a substrate and reaction orifices on the substrate, where the reaction orifices comprise 2-384 sample orifices and 2-8 standard product orifices, and at the bottom of each reaction orifice is solid carrier coated with micro lattice of HBsAg, HCVAg, AFP, AFU,MAO,and HA antigens /antibodies or more. And the reaction plate and reagent can simply and conveniently, quickly and accurately implement simultaneous detection of the six indexes of diagnosis, forecast and prognosis of hepatitis, hepatocirrhosis and liver cancer for many persons.

The invention discloses a cotton polyamine oxidase GhPAO2 gene and application thereof. The sequence of the cotton polyamine oxidase GhPAO2 gene is shown in SEQ ID No. 3. According to the invention, the root tissue of Jimian 20 is taken as raw material; the whole-length cDAN sequence of the cotton polyamine oxidase GhPAO2 gene is cloned through bioinformatics and the RT-PCR technology; the cotton polyamine oxidase GhPAO2 gene is constructed to a prokaryotic expression vector and expresses a heterologous protein in an escherichia coli Rosetta (DE3) successfully. An in-vitro experiment proves that purified cotton polyamine oxidase GhPAO2 GhPAO2 is a flavoprotein taking FAD as a prothetic group and has the activity of a spermidine oxidase and a spermine oxidase. A bacterial strain capable of expressing the cotton polyamine oxidase GhPAO2 and a contrast bacterial strain containing an empty carrier are treated with sodium chloride solution with different concentrations; with the same treatment, the quantity of cells of the transgenic bacterial strain is remarkably increased when compared with that of the cells of the contrast bacterial strain, which shows the expression of the cotton polyamine oxidase GhPAO2 in the escherichia coli improves the salt tolerance of the host bacteria.

The invention discloses escherichia coli recombinant bacteria capable of high-producing 2, 5-dimethylpyrazine and a construction method of the escherichia coli recombinant bacteria, and belongs to thetechnical field of gene engineering. According to the escherichia coli recombinant bacteria and the construction method thereof, a genetic engineering method is applied, L-threonine dehydrogenase TDHis overexpressed in escherichia coli K-12 capable of high-producing L-threonine, and NADH oxidase NoxE derived from lactococcus microorganisms and aminoacetone oxidase AAOSO derived from streptococcus microorganisms are expressed in a heterologous manner, and meanwhile 2-amino-3-ketobutyric acid CoA ligase KBL and primary amine oxidase TynA are knocked out, so that a novel and efficient 2, 5-dimethylpyrazine synthetic route is constructed, and the problem of unbalance of cofactors in the recombinant bacteria is solved. By taking escherichia coli E. coli THR as an example, the accumulation amount of 2, 5-dimethylpyrazine reaches 1.2 +/-0.2 g/L through a 36h shaking flask fermentation experiment of the recombinant bacteria. According to the method, L-threonine high-producing strains are used as starting strains, the synthetic route of 2, 5-dimethylpyrazine in escherichia coli is successfully reconstructed, the defect of unbalanced intracellular cofactors is improved, and a new idea is provided for breeding 2, 5-dimethylpyrazine.

The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and a phosphine oxide or amine oxide. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding a phosphine oxide or amine oxide to said formulation.

The invention relates to the technical field of medical testing and determination, and discloses a method and a kit for detecting monoamine oxidase. The method for detecting monoamine oxidase provided by the invention does not go through the hydrogen oxidation route, but uses the action of glutamic acid dehydrogenase to measure the decline rate of the reduced coenzyme reacting with ammonia to calculate the content of monoamine oxidase, thereby improving the accuracy of the detection result. The detection method of the present invention also includes mixing excessive lactate dehydrogenase with the sample to be tested, eliminating endogenous pyruvate in the sample during the reaction delay period, so that the reduced coenzyme reaches a balance, and the accuracy of monoamine oxidase detection is improved. The kit of the invention has good stability and long storage period, and the detection result by using the kit of the invention has high accuracy, good precision and wide linear range. The kit of the invention has a wide application range and is convenient for popularization and use, and can be applied to hospitals at all levels, health prevention departments and medical and biological scientific research units to determine the content of monoamine oxidase in serum.

The present invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual in which an effective amount of an amine oxidase enzyme inhibitor is administered to the individual. The invention also relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual in which a vitamin B1, its derivative, its precursor or metabolite is administered to the individual. In addition, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, as well as a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.

The present invention relates to a method for quantitative determination of an α-glycated peptide in a sample, comprising causing protease to act on a whole blood and/or blood cell sample, causing an elimination reagent containing one or a plurality of types of ketoamine oxidase to act on the resultant, eliminating an α-glycated amino acid, an ε-glycated amino acid, an ε-glycated peptide, or a combination thereof, and then determining the α-glycated peptide in the sample using oxidase that acts on the α-glycated peptide. The present invention also relates to an elimination reagent and a kit to be used for such method. According to the present invention, measurement errors in quantitative determination of a glycated protein such as glycated hemoglobin can be reduced, and thus a precise measured value can be obtained.

The present invention relates to a method for the deracemisation or chiral inversion of chiral amines by enzymatic treatment. The method employs a stereoselective enzymatic conversion and either a non-selective or partially selective chemical or enzymatic conversion, simultaneously or sequentially. The invention also provides a method for selecting a suitable enzyme, particularly a suitable amine oxidase, and for the generation of novel enzymes suitable for use in the deracemisation method.

The invention provides a formamide pyridone iron chelating agent derivative shown as a formula (I) or a formula (II) which is described in the specification and a preparation method and application thereof. The formamide pyridone iron chelating agent derivative shown in the formula (I) or the formula (II) and the pharmaceutically acceptable salt thereof have the effects of inhibiting monoamine oxidase, chelating metal iron ions, resisting A beta and resisting oxidation activity. The derivative can be used for preparing medicines for resisting Alzheimer's disease, Parkinson's disease or other diseases treated by inhibiting monoamine oxidase, chelating metal iron ions, resisting A beta and resisting oxidation.

The present invention provides a fructosylamine oxidase which is obtainable by culturing Fusarium proliferatum, and purifying two types of fructosylamine oxidase (FAO) with different substrate specificities from the culture, and which is useful in the measurement of amadori compounds.

The invention provides a small-molecule inhibitor SLD1338. The structural formula of the small-molecule inhibitor is as shown in the description. The small-molecule inhibitor SLD1338 is applied to preparing a drug for inhibiting spermine oxidase. The result shows that the SLD1338 changes the growth cycle of human small cell lung cancer A549 cells and changes the expression content of A549 cyclin,and meanwhile can induce apoptosis of the A549 cells.

The invention relates to a pyridone hexa-alkyne amine modified derivative as shown in a formula (I) and a pharmaceutically acceptable salt thereof, a preparation method thereof, application of the pyridone hexa-alkyne amine modified derivative or the pharmaceutically acceptable salt thereof to preparation of drugs for preventing or treating related diseases, especially Alzheimer's disease and Parkinson's disease, by inhibiting monoamine oxidase, chelating metal iron ions, resisting Abeta and resisting oxidation. According to the invention, a series of novel single-molecule multi-target anti-ADactive compounds are synthesized, and pyridone derivatives with iron ion chelating activity and propynylamine with MAOB inhibitory activity are creatively and organically combined together, so that the compounds have remarkable advantages on Alzheimer's disease with complex pathogenesis; and the combined molecules are far superior to CP20 (deferiprone) in the aspect of iron ion chelating activity.

The invention provides a small molecule inhibitor SLD4650. A structural formula of the small molecule inhibitor is shown in the description. The invention also discloses application of the small molecule inhibitor SLD4650 to preparation of medicines for inhibiting spermine oxidase. A result shows that the SLD4650 changes a cell growth period of human small-cell lung cancer A549, changes cell period protein expression content of the A549, and also can induce A549 cell apoptosis.

The invention discloses an HDAC/MAO-B dual inhibitor, preparation thereof and application of the HDAC/MAO-B dual inhibitor in preparation of drugs and neuroprotective antioxidants for preventing and treating related diseases by inhibiting monoamine oxidase and histone deacetylase. The HDAC/MAO-B dual inhibitor has the following general formula (I) or (II), wherein in the formula (I) and the formula (II), R is respectively and independently an aromatic group or a substituted aromatic group. The HDAC/MAO-B dual inhibitor not only has an HDAC inhibition effect, but also has an MAO-B inhibition effect, and is a multi-target hydroxamic acid/anthranilamide propargylamine type derivative which realizes nerve protection and oxidation resistance through cooperation of a propargylamine group and hydroxamic acid or anthranilamide group.

The invention belongs to the technical field of biology, relates to genetic engineering, biotransformation, bioconversion and biological catalysis, and organic synthesis technology, and discloses a monoamine oxidase gene from Aspergillus flavus and application thereof in chiral amine intermediate preparation using the monoamine oxidase gene to catalyze asymmetric oxidation reaction. The monoamineoxidase AaMAO7-6 gene is 1419 bp and encodes monoamine oxidase formed by 470 amino acids. After the recombinant monoamine oxidase built by the monoamine oxidase gene is expressed, the whole-cell or enzyme is used for transforming cis-7-aza-bicyclo[3,3,0]octane to generate the key chiral intermediate of Telaprevir. The preparation method is mild in reaction conditions, high in stereoselectivity, easy to achieve industrialization and the like.

The invention belongs to the field of medicine and chemical industry, and specifically discloses a 4-flexible amine-2-aryl vinyl quinoline derivative and a preparation method thereof, and applications of the 4-flexible amine-2-aryl vinyl quinoline derivative in preparation of anti-Alzheimer disease drugs, wherein the chemical formula of the 4-flexible amine-2-aryl vinyl quinoline derivative is defined in the specification. The invention further discloses the preparation method and the uses of the 4-flexible amine-2-aryl vinyl quinoline derivative. According to the present invention, the 4-flexible amine-2-aryl vinyl quinoline derivative has advantages of monoamine oxidase-B activity inhibiting, A[beta] aggregation resistance, anti-oxidation activity, metal complexing, low biological toxicity and good safety, such that the 4-flexible amine-2-aryl vinyl quinoline derivative has broad application space in the preparation of anti-Alzheimer disease drugs.

The present invention provides polynucleotides and related polypeptides of the enzyme APAO isolated from Exophiala spinifera and Rhinocladiella airovirens. The polynucleotides may be mutated to remove glycosylation sites and cysteine residues. Additionally, the present invention provides recombinant expression cassettes, host cells, transgenic plants, and transgenic seed. The present invention also provides for polynucleotides containing both APAO and a fumonisin esterase. In addition, the present invention provides methods for producing the APAO enzyme in both prokaryotic and eukaryotic systems, methods for detecting fumonisins, and methods for identifying transformed plant cells. Methods for degrading fungal toxins in plants, grain, grain processing, silage, food crops and in animal feed are also disclosed.